Compare IPCA Labs with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ASTRAZENECA PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ASTRAZENECA PHARMA IPCA LABS/
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.1 82.7 26.7% View Chart
P/BV x 4.3 23.3 18.4% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ASTRAZENECA PHARMA
Mar-18
IPCA LABS/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6951,278 54.4%   
Low Rs400883 45.3%   
Sales per share (Unadj.) Rs260.2228.4 113.9%  
Earnings per share (Unadj.) Rs19.010.4 183.1%  
Cash flow per share (Unadj.) Rs33.116.3 203.3%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.098.8 215.7%  
Shares outstanding (eoy) m126.2025.00 504.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.7 44.5%   
Avg P/E ratio x28.9104.2 27.7%  
P/CF ratio (eoy) x16.666.4 24.9%  
Price / Book Value ratio x2.610.9 23.5%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,12027,008 255.9%   
No. of employees `00013.31.4 977.4%   
Total wages/salary Rs m7,3591,535 479.3%   
Avg. sales/employee Rs Th2,477.44,210.9 58.8%   
Avg. wages/employee Rs Th555.21,132.2 49.0%   
Avg. net profit/employee Rs Th180.6191.1 94.5%   
INCOME DATA
Net Sales Rs m32,8365,710 575.1%  
Other income Rs m418123 341.2%   
Total revenues Rs m33,2545,833 570.1%   
Gross profit Rs m4,505463 973.2%  
Depreciation Rs m1,777147 1,205.8%   
Interest Rs m2400-   
Profit before tax Rs m2,905438 663.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511179 285.7%   
Profit after tax Rs m2,394259 924.0%  
Gross profit margin %13.78.1 169.2%  
Effective tax rate %17.640.8 43.1%   
Net profit margin %7.34.5 160.7%  
BALANCE SHEET DATA
Current assets Rs m19,4553,209 606.2%   
Current liabilities Rs m10,0762,070 486.9%   
Net working cap to sales %28.620.0 143.1%  
Current ratio x1.91.6 124.5%  
Inventory Days Days9872 135.3%  
Debtors Days Days6735 191.7%  
Net fixed assets Rs m20,260790 2,563.5%   
Share capital Rs m25250 504.8%   
"Free" reserves Rs m26,6332,419 1,100.9%   
Net worth Rs m26,8862,469 1,088.8%   
Long term debt Rs m2,3400-   
Total assets Rs m41,1734,605 894.0%  
Interest coverage x13.1NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.81.2 64.3%   
Return on assets %6.45.6 113.7%  
Return on equity %8.910.5 84.9%  
Return on capital %10.817.7 60.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,642300 5,221.9%   
Fx outflow Rs m4,8842,015 242.4%   
Net fx Rs m10,759-1,715 -627.2%   
CASH FLOW
From Operations Rs m3,41188 3,880.9%  
From Investments Rs m-1,354-94 1,446.6%  
From Financial Activity Rs m-1,304NA-  
Net Cashflow Rs m753-6 -13,214.0%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 15.7 161.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 12,856 287.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare IPCA LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

ASTRAZENECA PHARMA Surges by 6%; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Oct 17, 2019 | Updated on Oct 17, 2019

ASTRAZENECA PHARMA share price has surged by 6% and its current market price is Rs 2,331. The BSE HEALTHCARE is up by 0.1%. The top gainers in the BSE HEALTHCARE Index is ASTRAZENECA PHARMA (up 5.6%). The top losers are THYROCARE TECHNOLOGIES (down 0.1%) and LAURUS LABS LTD (down 0.2%).

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Oct 17, 2019 03:37 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS